CTOs on the Move

Medically Home

www.medicallyhome.com

 
We bring the hospital to you! We deliver advanced medical care to where and when patients and their families want and need it. The Medically Home Program gives you more care over a longer period of time. We know getting well from a hospital-level illness or surgical procedure takes weeks, not days. With the Medically Home Program, you get the time you need - at home - with a single care team available to you the entire time. One of the secrets to getting better is being involved in – and understanding – your own care. The more time you ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Medically Home raised $10M on 05/28/2019
Medically Home raised $40.4M on 11/04/2020
Medically Home raised $100M on 05/13/2021

Similar Companies

Zotec Partners

Zotec Partners is an industry leading provider of specialized medical billing and practice management services for the hospital-based specialty market. The company is committed to the continual pursuit of excellence in the physician revenue cycle management industry by delivering effective solutions through personalized service and measurable client results. Zotec Partners` proprietary processes and technology manage in excess of 70 million medical encounters across all 50 states.

Princeton HealthCare System

Princeton HealthCare System, Inc. is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Princeton HealthCare System, Inc. is based in Plainsboro, NJ. You can find more information on Princeton HealthCare System, Inc. at www.princetonhcs.org

EnduraCare

EnduraCare Therapy Management is the largest privately held provider of rehabilitation services.

New Chapter Inc.

New Chapter Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

ProKidney

ProKidney, a pioneer in the treatment of chronic kidney disease (CKD) through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney`s lead product candidate, REACT® (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases drive meaningful improvement in kidney function. REACT® has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting an immediate start to a global registrational program, which launched in the United States on schedule in January 2022. On January 18, 2022, ProKidney announced that it would become a publicly traded company via a business combination with Social Capital Suvretta Holdings Corp. III